Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 20/20 | 0.68 |
| ▸ | PPARA | Q07869 | 13/20 | 0.64 |
| ▸ | PPARD | Q03181 | 4/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385736 | 0.95 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6385296 | 0.95 | PPARG (0.71) | PPARGPPARAPPARD | |
| SCHEMBL6384193 | 0.93 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6383296 | 0.92 | PPARG (0.67) | PPARGPPARAPPARD | |
| SCHEMBL6385567 | 0.89 | PPARG (0.70) | PPARGPPARAPPARD | |
| SCHEMBL6385055 | 0.88 | PPARG (0.68) | PPARGPPARAPPARD | |
| SCHEMBL6383173 | 0.87 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL6382693 | 0.87 | PPARG (0.76) | PPARGPPARAPPARD | |
| SCHEMBL7904793 | 0.87 | PPARG (0.75) | PPARGPPARAPPARD | |
| SCHEMBL7904779 | 0.86 | PPARG (0.77) | PPARGPPARAPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1423363-A1 | ORAL ANTIDIABETIC AGENTS | Warner-Lambert Company LLC (US) | 2004-06-02 | — | — | EP | claimed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | claimed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | claimed |
| EP-1577305-A1 | Oral antidiabetic agents | WARNER-LAMBERT COMPANY LLC (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1423363-A1 | ORAL ANTIDIABETIC AGENTS | Warner-Lambert Company LLC (US) | 2004-06-02 | — | — | EP | disclosed |
| US-20030171377-A1 | Antidiabetic agents | BIGGE CHRISTOPHER FRANKLIN (US) | 2003-09-11 | — | — | US | disclosed |
| WO-2003018553-A1 | ORAL ANTIDIABETIC AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171377-A1 | Antidiabetic agents | SLC5A1, SLC5A2, GLP1R | PPARG 280/4885PPARA 439/4885PPARD 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.